Plus stock rises as radiotherapy shows promise in ongoing brain cancer studies

Nov. 21, 2022 6:23 AM ETPlus Therapeutics, Inc. (PSTV)By: Ravikash, SA News Editor

Medical Science Hospital: Confident Black Female Neurologist, Neuroscientist, Neurosurgeon, Looks at TV Screen with MRI Scan with Brain Images, Thinks about Sick Patient Treatment Method. Saving Lives

gorodenkoff

Plus Therapeutics (NASDAQ:PSTV) reported updated data from two ongoing trials of its radiotherapy rhenium (186Re) obisbemeda in patients with recurrent glioblastoma (GBM), and leptomeningeal metastases (LM).

GBM is a type of cancer that affects the brain or spinal cord, while LM occurs when the cancer

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.